Efficacy and Safety of tDCS and tACS in Treatment of Major Depressive Disorder: A Randomized, Double-Blind, Factorial Placebo-Controlled Study Design
Yuxin Huang,Linjie Shen,Jia Huang,Xianrong Xu,Yong Wang,Hua Jin
DOI: https://doi.org/10.2147/NDT.S295945
IF: 2.989
2021-05-13
Neuropsychiatric Disease and Treatment
Abstract:Yuxin Huang, 1 Linjie Shen, 1 Jia Huang, 1 Xianrong Xu, 2 Yong Wang, 1 Hua Jin 1 1 Department of Outpatient, Shanghai Mental Health Center, Shanghai, People's Republic of China; 2 School of Public Health, Hangzhou Normal University, Hnagzhou, Zhejiang Province, People's Republic of China Correspondence: Yong Wang Department of Outpatient, Shanghai Mental Health Center, No. 600 Wanping South Road, Xuhui District, Shanghai, People's Republic of China Tel +86-18017311332 Email Background: Transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation (tACS) are regarded as promising antidepressant treatments. Objective: To compare the efficacy and safety of tDCS, tACS, escitalopram, and placebo/sham stimulation controls. Design: Randomized, parallel, double-blind, placebo-controlled study. Methods: Sample sizes were calculated based on data from previous similar studies. Eligible non-treatment-resistant-depressive outpatient subjects with moderate-to-severe depression (HRDS ≥ 17) are randomized to receive (1) tDCS + placebo; (2) tACS + placebo; (3) escitalopram + placebo; or (4) sham stimulation + placebo. The intensity of electricity is 2 mA, lasting for 30 minutes over two consecutive working days (10 sessions in total). The medication lasts for 6 weeks. The primary outcome measure was the response rates within 6 weeks (week 6 is also the endpoint of the study), and secondary outcome measures included changes in other clinical measurements. Safety and acceptability are measured by adverse event rates and dropout rates. Exploring outcome consist of the performance of cognitive battery as well as neurophysiology results. Conclusion: To the best of our knowledge, the present study is the first double-blind controlled study comparing tDCS, tACS, and clinically used antidepressants, which will provide further evidence for their efficacy and safety in possible clinical applications. Keywords: transcranial direct current stimulation, tDCS, transcranial alternating current stimulation, tACS, electrical stimulation, major depressive disorder, MDD Major depressive disorder (MDD) is a widespread neuropsychiatric disorder with an estimated 12-month prevalence of 2.1% and a lifetime prevalence of 3.4% in China 1 . Currently, the predominant treatment for MDD is antidepressant drugs, which only brings about 1/3 clinical remission rate. 2 , 3 Meanwhile, antidepressant drugs usually result in undesirable side effects and undergo 2–4 weeks to achieve clinical efficacy. Therefore, it is necessary to explore other alternative efficient approaches. Non-invasive physical therapy interventions, including transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation (tACS), have attracted the researchers' attention. Both tDCS and tACS stimulate the brain through scalp electrodes to modulate cortical activity, whose benefits include painlessness, causing few adverse events, portable, easy to operate, and economic. TDCS delivers direct currents (0.5–2 mA) to the scalp to modulate the neural activity of the cerebrum. 4 , 5 Its exact mechanism has yet to be defined. 5 The stimulatory effect of tDCS is characterized by polarity regulation: the anode current promotes depolarization of neuronal membrane potentials to enhance cortical excitability, and the cathode current induces hyperpolarization changes to inhibit cortical excitability. 6 TDCS potentially improves cognitive performances, such as reduction in response time 7 and vigilance to threat, 8 and improved emotion recognition. 9 However, there is insufficient evidence to state that tDCS has a positive or negative effect as a treatment for depression cognitive dysfunction 10 and should therefore be further investigated. Evidence of tDCS' efficacy on a depressive episode remains inconsistent, 11 , 12 in part due to various confounding variables (ie, tDCS parameter settings, outcome measures, etc.) that are not under controlled. The effects of tDCS varying by individuals 13 may also contribute to the heterogeneous results. The structural traits and functional states of individuals neural systems are considered the main sources of the individual sensitivity to tDCS. 14 In addi -Abstract Truncated-
psychiatry,clinical neurology